Tildrakizumab improves high burdensome symptoms and overall well-being in patients with moderate-to-severe plaque psoriasis
Loading...
Date
Journal Title
Journal ISSN
Volume Title
dc.identifier.issn
0190-9622
1097-6787
1097-6787
dc.identifier.doi
dc.identifier.other
dc.description.volume
93
dc.description.issue
3
Publisher
MOSBY-ELSEVIER